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Abstract: Obesity and hyperlipidemia are the most prevalent independent risk factors of chronic
kidney disease (CKD), suggesting that lipid accumulation in the renal parenchyma is detrimental to
renal function. Non-esterified fatty acids (also known as free fatty acids, FFA) are especially harmful
to the kidneys. A concerted, increased FFA uptake due to high fat diets, overexpression of fatty acid
uptake systems such as the CD36 scavenger receptor and the fatty acid transport proteins, and a
reduced β-oxidation rate underlie the intracellular lipid accumulation in non-adipose tissues. FFAs
in excess can damage podocytes, proximal tubular epithelial cells and the tubulointerstitial tissue
through various mechanisms, in particular by boosting the production of reactive oxygen species
(ROS) and lipid peroxidation, promoting mitochondrial damage and tissue inflammation, which
result in glomerular and tubular lesions. Not all lipids are bad for the kidneys: polyunsaturated
fatty acids (PUFA) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) seem to
help lag the progression of chronic kidney disease (CKD). Lifestyle interventions, especially dietary
adjustments, and lipid-lowering drugs can contribute to improve the clinical outcome of patients
with CKD.
Keywords: lipid accumulation; blood lipids; metabolic disease; chronic kidney disease; potential
therapeutic strategy
1. Introduction
Chronic kidney disease (CKD) is defined by a reduced glomerular filtration rate (GFR) to less than
60 mL/min per 1.73 m2 and/or alteration of kidney damage marker values (e.g., proteinuria) of at least
3 months duration, regardless of the underlying cause [1]. The latest data from the Global Burden of
Disease (GBD), Injuries, and Risk Factors study reported that, worldwide, CKD-related morbidity and
mortality are rising—a trend that also carries a substantial financial burden [2]. Currently, the costs for
the treatment and care of patients with CKD outrank those for other common diseases [3].
The etiopathogenesis of CKD is still unclear, yet a plethora of risk factors has been identified.
Among these, obesity and hyperlipidemia are becoming more and more prevalent. In particular, obesity
seems to be strictly interrelated with CKD [4]. Consistently, CKD shares a number of key features
with the obesity-related glomerulopathy (ORG), which is characterized by glomerular enlargement,
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focal and segmental sclerosis (FSGS), damage of the peritubular capillaries, and retrograde glomerular
changes [5–7]. This review systematically describes the link between lipids and CKD development
and progression from epidemiological, clinical and pathophysiological angles, and it provides new
insights into the potential lipid-related therapeutic approaches for patients with CKD.
2. Epidemiological Studies
People with elevated body mass index (BMI) have a higher risk of developing CKD compared
to individuals with a BMI in the normal range [2]. It has been estimated that for each BMI unit in
excess, the risk of CKD augments by 5% [2]. Obesity is now considered an independent risk factor for
CKD onset [8]. Additionally, obesity is also a risk factor for hypertension and cardiovascular diseases,
which are themselves risk factors for CKD [9]. Obesity-related events have a detrimental influence on
renal function and have been linked to end-stage renal disease [10]. The prevalent hypothesis is that
individuals with a high BMI (≥25 kg/m2) experience substantial changes in renal hemodynamics (GFR,
renal plasma flow and filtration fraction), perhaps as a result of excessive sodium intake, increasing
their risk of long-term kidney damage [11,12]. However, other abnormalities, often co-existing in
obese individuals, such as insulin resistance and hyperlipidemia may contribute to the renal damage.
In addition, patients with one or more of these factors are more prone to develop CKD as they gain
weight [4,13]. A survey of 5897 hypertensive patients showed that after the adjustment for covariates
such as diabetes, both baseline overweight (Odds Ratio: 1.21, 95% CI: 1.05–1.41) and obesity (Odds
Ratio: 1.40, 95% CI, 1.20–1.63) were associated with CKD [4]. The visceral adiposity index and the lipid
accumulation product index positively correlated with CKD [14,15].
In the early 1990s, large-scale and case studies proposed a link between hyperlipidemia and
CKD. After 10 years of follow-up, it was found that the hazard ratio of proteinuria increased in
both genders in CKD patients with hypercholesterolemia, low high-density lipoprotein levels (HDL),
and high triglyceride levels [16]. A cross-sectional community-based Japanese study associated
hyperlipoproteinemia with low estimated GFR [17]. In a meta-analysis by Weiner, 90% of the patients
with CKD displayed total cholesterol levels higher than 240 mg/dL, and more than 80% of the patients
with CKD who were not treated with hemodialysis, had low-density lipoprotein (LDL) levels above
130 mg/dL [18]. This finding was confirmed by two following studies [19,20]. Besides the cholesterol
and triglyceride (esterified fatty acids) levels, the excess of non-esterified fatty acids (also known as
free fatty acids, NEFAs or FFAs) and long polyunsaturated complex lipids can aggravate CKD patient’s
condition [21]. There is enough epidemiological evidence to hypothesize a causative link between
lipid accumulation and the development and progression of CKD.
3. The Mechanism of Lipid Transport and Metabolism in the Kidneys
Hyperlipidemia is caused by an abnormal lipid intake and/or metabolism, resulting in
hypercholesterolemia, hypertriglyceridemia, or both (combined hyperlipidemia) [22]. When energy
intake gradually exceeds the body’s ability to store fat in adipose tissue (white adipose tissue),
circulating lipids from various sources spill over into non-adipose tissue, such as muscle, liver, kidneys,
and pancreas; this phenomenon is called “ectopic lipid accumulation” [23]. In the kidneys, lipids
can sediment in virtually all cell types, from mesangial cells to podocytes and proximal tubule
epithelial cells. For instance, in mice fed a high-fat diet (HFD), the high systemic levels of neutral
lipids (e.g., cholesterol) and phospholipids lead to “fatty” proximal tubules (Figure 1, own data) [24].
Moreover, lipid levels continue to increase with the progression of kidney lesions [25,26].
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Figure 1. Representative images of BODIPY staining (A and B) in kidney sections from chow diet (A) 
and high fat diet (HFD) (B) mice. Scale bar = 50 μm. Analysis of BODIPY staining in different kidney 
sections (C). Total cholesterol content in the kidney from different groups (D). n = 6 mice/group, *p < 
0.05. Representative images of immunostaining for FATP4 (E and F) and 4-HNE (G and H) in kidney 
sections from chow and HFD mice. Scale bar = 50 μm. 
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macrophages, CD36 levels were shown to correlate with the intracellular levels of ox-LDL [35]. 
Ox-LDL are metabolized to 9-hydroxyoctadecenoic acid and 13-octadecenoic acid, which activate 
the peroxisome proliferator-activated receptor γ (PPARγ), a transcription factor involved in 
adipogenesis. PPARγ activation also institutes a positive feedback by trans-activating the CD36 gene 
promoter, thus increasing CD36 expression [36]. In podocytes, CD36-mediated palmitic acid uptake 
resulted in a dose-dependent increase in reactive oxygen species (ROS) levels, mitochondrial 
membrane potential depolarization, ATP depletion, and activation of the apoptotic pathways 
[32,37,38]. Additionally, it was shown in animals that FAs can trigger apoptosis of renal tubular 
epithelial cells and podocytes by inducing the expression of thrombospondin 1, a ligand of CD36 
[39,40]. 
Possessing a positively charged binding pocket, CD36 preferentially binds negatively charged 
ligands. Besides ox-LDL, advanced oxidation protein products (AOPPs), and advanced glycation 
end products (AGEs), which are known to promote inflammation and atherosclerosis, are 
recognized by CD36 as substrates [41]. Phosphorylation, glycosylation, and palmitoylation of the 
extracellular site of CD36 can affect FA uptake rate as well, nevertheless whether the 
post-translational modification pattern of CD36 is affected by obesity and hyperlipidemia has not 
been studied yet [42–46]. CD36 can also interact with the Na+/K+-ATPase and promote inflammation 
and oxidative stress upon binding to a variety of circulating ligands (e.g., cardiotonic steroids). 
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3.1. Lipid Uptake by CD36 in the Kidney
CD36 is a multifunctional transmembrane glycoprotein that mediates the uptake of oxidized LDL
(ox-LDL) [27]. Loss of function mutations in the CD36 gene cause abnormal levels of plasma fatty acids
(FA) and triglycerides in mice [28]. CD36 is the main FA uptake system in the kidneys and appears to
play a central role in CKD development and progression. Higher renal levels of CD36 wer found in
patients and a imals with kidney d mage [29]. Kidney CD36 expression levels wer higher in CKD
patients with diabetic nephropathy and were associated with altered renal lipid accumulation [20,30].
Chronic inflammation, a feature of obesity, is known to induce CD36 expression, which can aggravate
kidney damage and accelerate the disease progression [30]. Mice lacking CD36 displayed lower
renal lipid accumulation and were less susceptible to ki ney damage and related c mplications in
comparison with the respective wild-typ nimals [30].
CD36 is highly expressed in renal proximal and distal tubular epithelial cells, podocytes, mesangial
cells, microvascular endothelial cells, and interstitial macrophages (Figure 2) [30–34]. In macrophages,
CD36 levels were shown to correlate with the intracellular levels of ox-LDL [35]. Ox-LDL are
metabolized to 9-hydroxyoctadecenoic acid and 13-octadecenoic acid, which activate the peroxisome
proliferator-act vate r ce tor γ (PPARγ), a tr nscription factor involved in adipogenesis. PPARγ
activation also institutes a ositive feedback by trans-activating the CD36 gene promoter, thus
increasing CD36 expression [36]. In podocytes, CD36-mediated palmitic acid uptake resulted in
a dose-dependent increase in reactive oxygen species (ROS) levels, mitochondrial membrane potential
depolarization, ATP depletion, and activation of the apoptotic pathways [32,37,38]. Additionally,
it was shown in animals that FAs can trigger apoptosis of renal tubular epithelial cells and podocytes
by inducing the expression of thrombospondin 1, a ligand o CD36 [39,40].
Possessing a positively charged binding ocket, CD36 prefere tially binds negatively charged
ligands. Besides ox-LDL, advanced oxidation protein products (AOPPs), and advanced glycation
end products (AGEs), which are known to promote inflammation and atherosclerosis, are recognized
by CD36 as substrates [41]. Phosphorylation, glycosylation, and palmitoylation of the extracellular
site of CD36 can affect FA uptake rate as well, nevertheless whether the post-translational modification
pattern of CD36 is affected by obesity and hyperlipidemia has not been studied yet [42–46]. CD36 can
also interact with the Na+/K+-ATPase and promote inflammation and oxidative stress upon binding
to a variety of circulating ligands (e.g., cardiotonic steroids). Several of these ligands are increased
by high fat diet, potentiating this CD36/Na+/K+-ATPase-dependent inflammatory paracrine loop
between proximal tubule cells and macrophages, and thereby facilitating the development of chronic
inflammation, oxidant stress, and fibrosis underlying the renal dysfunction [30].
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3.2. Lipid Uptake by Other Transporters
Several fatty acid transport proteins (FATPs, SLC27A1-6) facilitate FFA cellular uptake
(Figure 2) [47–49]. Recent studies indicate that an abnormal FATP-mediated transport directly affects
lipid homeostasis, which, in turn, can trigger obesity, dyslipidemia, diabetes, and other diseases [50,51].
Figure 1 shows that FATP4 expression was higher in mice fed a HFD (own data). These animals also
displayed a higher degree of lipid peroxidation (4-Hydroxynonenal, 4-HNE, own data).
While knowledge of the physiological role of FATP comes mainly from studies on adipose
tissues, some members of this family, specifically FATP1 (SLC27A1), FATP2 (SLC27A2), and FATP4
(SLC27A4), are also highly expressed in the kidneys [48]. FATP1 is a peri-membranous protein, which
are trafficked to the cell surface in response to insulin [52]. The function of FATP1 has been mainly
characterized in the adipose tissue, in which the expression is induced when preadipocytes differentiate
into adipocytes [49]. FATP2 has been shown in mice to regulate lipid synthesis in the kidney—the
repression of FATP2 led to the decrease of acyl-CoA synthetase activity in the kidney, resulting in a
reduced lipid synthesis in the endoplasmic reticulum (ER) [53,54]. The transport of FFAs into the ER
is mainly mediated by FATP4. FATP4 functions as an acyl-CoA synthetase with preference for very
long-chain fatty acids [55]. FATP4 expression and polymorphisms have been associated with human
insulin resistance and obesity [56].
Other membrane proteins that can facilitate FA uptake are the plasma membrane fatty
acid-binding protein (FABPpm) (Figure 2) [57]. FABPs are members of the lipid-binding protein
superfamily that preferentially recognize long-chain fatty acids as substrates. In spite of the
names, the epidermal FABP (E-FABP), the liver-type FABP (L-FABP) and the heart-type FABP
(H-FABP) are those expressed in the kidney and appear to be physiologically redundant [58]. In
fact, in animals, the deletion of the L-FABP gene resulted in increased expression of E-FABP and
cholesterol accumulation [59]. FABPs also facilitate the polyunsaturated FA-induced transactivation of
PPARα and PPARγ via direct interaction with the nuclear receptor’s ligand binding domain [60–64].
FAs also induce FABP expression [65]. In the rat kidney disease model, high levels of L-FABP promoted
the proliferation of rat tubular epithelial cells and aggravated interstitial inflammation [66].
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Figure 2. Schematic representation of fatty acids cellular uptake in the kidneys. FA transport across the
plasma membrane occurs mainly by protein-mediated mechanisms either with CD36 or with FATPs.
In the cells, FAs bind to different FABPs with respect to the subcellular localization and have multiple
functions in energy generation and storage, membrane synthesis and activation of nuclear transcription
factors like PPAR/RXR. NEFA, non-esterified fatty acid; FATP, fatty acid transport protein; FABP,
fatty acid-binding protein; PPAR, peroxisome proliferator activated receptor; RXR, retinoid X receptor;
TG, triglyceride.
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3.3. Regulation of Lipogenesis in the Kidney
The regulation of lipogenesis is mediated by a number of transcriptional factors such as the
CCAAT/enhancer-binding protein α (C/EBPα), PPARγ, sterol regulatory element-binding protein
1 (SREBP-1) and farnesoid X receptor (FXR) [67]. The C/EBPα fine-tunes glucose homeostasis
by indirectly regulating insulin signaling but also participates in the regulation of triglycerides
synthesis [68]. In diabetic rats, the expression of SREBP-1, induced by high glucose diet, induced
fatty acid synthesis [69]. It has been shown that the hepatic lipid content raised as a result of the
repression of several enzymes involved in mitochondrial β-oxidation and the overexpression of
carbohydrate-responsive element-binding proteins and their target genes, which are the main
regulators fatty acids synthesis, suggesting that lipogenesis regulation occurs mainly by modulating
fatty acid β-oxidation in the mitochondria [70]. This might also happen in the kidney, albeit no
experimental evidence is reported. In a recent work, the adipose triglyceride lipase (ATGL), which
catalyzes the initial step in triglyceride hydrolysis in adipocyte, was also found to affect renal
lipid content. ATGL-deficient mice exhibit significantly higher triglycerides levels in the kidney
in comparison with the respective wild-type animals, accompanied by proteinuria [71]. Other potential
mechanisms of lipid accumulation in the kidneys may be related to the dysregulation of multipotent
mesenchymal progenitor cells (MMPCs). In fact, in certain conditions MMPCs can represent an
additional pre-fat cell population. MMPC differentiation disorder has been hypothesized to be related
to the uremic environment secondary to the low renal performance [72].
4. Lipid-Induced Renal Damage
Most studies have focused on the lipid nephrotoxicity hypothesis based on Moorhead’s work [26].
Scholars who support this hypothesis believe that hyperlipidemia can lead to inflammation, ROS
production and endogenous electrical stress. There are pieces of evidence that renal lipid accumulation
can cause structural and functional changes in mesangial cells, podocytes and proximal tubule cells,
which all contribute to the nephron function [73]. However, to date, there is only limited evidence for
an association of lipid accumulation with kidney disease.
One of the main sites of renal lipid accumulation is the renal proximal tubule cells. High levels of
albumin-bound long-chain saturated fatty acids were shown to promote the progression of renal
tubular damage and interstitial fibrosis; excess of Ox-HDL induced pro-inflammatory pathways,
including tumor necrosis factor-alpha (TNF-α), CC motif chemokine 2 and interleukin-6 (IL-6), and
increased the production of ROS [30,74,75]. Recent animal studies have shown that deletion of the
gene encoding for the biliverdin reductase A (BVRA) caused lipid accumulation and toxicity in
mouse proximal tubular cells, and this may be related to impaired mitochondrial respiration and
β-oxidation [20]. BVRA was also shown to protect the kidney by modulating insulin signaling [76].
Renal tubule genome-wide analysis showed that in both mice and human renal interstitial fibrosis
models, there was a lower expression of numerous important mitochondrial enzymes, and fatty acid
oxidation adjustment factors, such as PPARα and PPARγ, resulting in increased lipid deposition
in cells [77]. Accumulation of triglycerides was also found to accelerate renal tubule fibrosis [26].
Proximal tubule cells seem to be more susceptible to lipid toxicity than the other cell population of
the kidneys, perhaps because they require higher energy expenditure, which can only be supplied by
oxidative phosphorylation at the mitochondrial level. Hence, lipid-induced mitochondrial damage
might be particularly catastrophic for proximal tubule cells [78,79].
Lipid-induced toxicity also contributes to the development of glomerulosclerosis. Kidneys from
rats fed a HFD for 32 weeks were characterized by chronic inflammation, high ROS level, and fibrosis
in the glomeruli [34]. In patients with obesity-related proteinuria, renal biopsies showed glomerular
hypertrophy and FSGS lesions, perhaps due to inhibition of the AMPK/PGC1α pathway secondary
to the accumulation of sphingomyelin in mesangial cells [80,81]. Lipid-induced glomerulosclerosis
may also be the result of the concerted activation of SREBP-1, transforming growth factor 1 (TGF-1),
vascular endothelial growth factor (VEGF), and inflammatory pathways [69,73]. Rats on HFD with
Nutrients 2019, 11, 722 6 of 21
chronic inflammation developed severe renal degeneration and glomerular damage, indicating that the
aggravation of obesity may itself exacerbate existing kidney damage, perhaps due to the overexpression
of CD36, TNFα, IL-6, and monocyte chemotactic protein-1 (MCP-1) during inflammation, which results
in the thickening of the glomerular basement membrane, extracellular matrix, glomerulosclerosis [34].
In particular, lipid accumulation can initiate ER stress to enhance TNFα or IL-6 in HMC and HK2
cells, resulting in the increased production of ROS and direct toxic effects on the kidney [34]. Elevated
levels of ROS markers will aggravate endothelial dysfunction and vascular disease in CKD and
cause an increase in uremic toxins [82]. Podocytes represent another type of cells whose damage
contributes to glomerulosclerosis and albuminuria in CKD. Podocytes adhere to the outside of the
glomerular basement membrane (GBM), together with the vascular endothelial cells and the glomerular
basement membrane, and constitute a glomerular hemofiltration barrier. Current findings in mice
provide evidence that CD36 can interact with thrombospondin-1 (TSP-1) in podocytes, and triggers
apoptosis [39]. Podocyte dysfunction and apoptotic rate were reduced in obese mice lacking TSP-1
compared to the wild type obese [40]. In the ATGL-deficient mouse model, which is characterized by
renal lipid accumulation and proteinuria, the rate of apoptotic podocytes is elevated in comparison
with that of podocytes from wild type animals. The transient silencing of ATGL could promote
podocyte apoptosis, which might be the result of increase of ROS, actin rearrangement and foot process
fusion [71].
5. Treatment
5.1. Bile Acid Receptor Agonists
The farnesoid x receptor (FXR) is a bile acid nuclear receptor abundant in the intestine and in the
liver and recently found highly expressed also in the kidney [83]. Because it is a key modulator of
bile acid and lipid metabolism, and limits the production of ROS, pro-inflammatory cytokines and
pro-fibrotic growth factors, FXR represents a potential target for the treatment of CKD [83,84]. Studies
have shown that in HFD-induced obese mice, the treatment with a FXR agonist reduced plasma
total cholesterol concentration by downregulating the expression level of SREBP-1 in different tissues,
including the kidneys [83]. The treatment of obese mice with the semi-synthetic FXR agonist obeticholic
acid (OCA) reduced the degree of glomerular sclerosis and tubulointerstitial injury by improving
mitochondrial function and promoting FA oxidation, which, in turn, reduced mitochondrial stress and
the ER stress [84]. In another study, administration of OCA to mice with ischemia/reperfusion kidney
damage could prevent early-stage renal damage by reducing monocyte infiltration and oxidative
stress, thereby protecting the kidney from CKD on the long term [85]. In addition, a recent study
on non-alcoholic fatty liver disease has shown that the anti-inflammatory effect of FXR activation
was the result of a switch in arachidonic acid metabolism: from pro-inflammatory (leukotrienes) to
anti-inflammatory (epoxyeicosatrienoic acids) [86]. Pharmacological activation of FXR appears to be
safe and can represent a valid treatment option for the continuously increasing number of overweight
patients with CKD [86,87].
The G protein-coupled bile acid receptor GPBAR1 (TGR5) is a member of the G protein-coupled
receptor (GPCR) superfamily and is a bile acid receptor, which plays a key role in the regulation
of energy consumption and glucose homeostasis. Because its expression and activity were found
reduced in the kidneys of obese and diabetic individuals, TGR5 appears to be an intriguing target for
the treatment of metabolic diseases such as type 2 diabetes and obesity [88,89]. Mice fed a HFD had
decreased blood glucose and insulin levels after treatment with a natural TGR5 agonist (a triterpene,
i.e., oleanolic acid contained in olive leaves), and prevented the animals fed a HFD from gaining
weight [88]. In another animal study, the use of the TGR5 agonist INT-777 could reduce urinary
albumin excretion, glomerular mesangial expansion, and accumulation of extracellular matrix proteins
and plasma triglycerides in obese mice with kidney dysfunction [90]. The activation of TGR5 prevented
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the progression of nephropathy in diabetic and obese animals by inducing mitochondrial biogenesis
and preventing lipid accumulation and oxidative stress [91].
5.2. PPAR Agonists
PPARα is a member of the ligand-activated transcription factor nuclear receptor superfamily
and it is primarily involved in fatty acid β-oxidation and lipolysis [92,93]. PPARα is expressed
both in glomerular and tubular cells. Fenofibrate, a potent PPARα agonist, was shown to reduce
systemic triglyceride levels, renal oxidative stress, proteinuria and glomerular sclerosis with an overall
improvement of the renal function in mice fed a HFD [94,95].
PPARγ regulates lipogenesis and is abundantly expressed in adipocytes and immune
cells [96]. PPARγ activation increases insulin sensitivity, which in turn lowers serum glucose
concentrations [97,98]. Because endogenous ligands such as long chain polyunsaturated fatty
acids and eicosanoid derivatives can activate PPARγ, it is conceivable that PPARγ agonists can
be used for reducing lipid systemic levels and renal lipid accumulation in obese patients with
CKD [99,100]. Thiazolidinediones-like PPARγ agonists, such as rosiglitazone, significantly reduced
blood glucose and triglyceride concentrations, and insulin resistance in diabetic (db/db) mice [101].
Insulin resistance is also a common feature in patients with CKD. In a randomized, double blind,
placebo-controlled study, 8-weeks treatment of rosiglitazone in CKD subjects lowered the homoeostasis
model assessment (HOMA) score and high-sensitivity C-reactive protein (hs-CRP), indicating an
increased insulin sensitivity in patients with CKD treated with rosiglitazone [102]. The inhibition
of the Wnt signaling-mediated fibrogenesis may represent another mechanism of kidney protection
by PPARγ activation [103,104]. Moreover, PPARγ also participates in the regulation of antioxidant
production, including superoxide dismutase 2 and glutathione peroxidase 1, which play important
roles in metabolic disorders and progression of CKD [105].
5.3. C/EBPα and C/EBPβ Inhibition
The C/EBPα is a major transcription factor in lipogenesis and it is involved in the stimulation
of the mononuclear phagocyte system, which increases oxidative stress and inflammation [106–110].
Interstitial fibrosis is prominent in the kidneys of patients with end-stage CKD [111]. Fibrosis lesion
degree, infiltration degree, and fibrosis proportion were found to positively correlate with C/EBPα
expression [112]. Thus, lipid accumulation may contribute to the activation of the mononuclear
phagocyte system and inflammation. Macrophage phagocytes can also oxidize lipids and transform
into foam cells, which, in turn, recruit more macrophages that aggravate the lesions, lipid deposition,
endothelial cell function, and vascular smooth muscle cell (VSMC) proliferation [113].
C/EBPβ is an essential factor in initiating several transcriptional cascades [114]. Knocking down
C/EBPβ in 3T3-L1 preadipocytes could block adipogenesis, whereas C/EBPβ overexpression was
sufficient to induce the differentiation of 3T3-L1 into adipocytes [115–117]. The C/EBPβ is also
involved in mitotic clonal expansion (MCE), an essential process for terminal adipocyte differentiation.
In C/EBPβ(−/−) mice, embryonic fibroblasts were not able to initiate the MCE process, hence could
not differentiate into adipocytes [114,116]. These findings suggest that C/EBPβ can have an effect
on renal lipid accumulation in patients with CKD, and the data reported here appear to support the
assumption that C/EBPβ can be used as the therapeutic target of CKD.
5.4. CD36 Antagonists
As mentioned above, there is a strong link between CD36 and lipid accumulation in renal
tissues. Therefore, CD36 is an intriguing target in CKD treatment. A recent study has shown that
in nephrectomized mice, the use of the CD36 antagonist 5A peptide (an apoA-I-mimetic peptide)
could reduce the degree of renal inflammation and tubulointerstitial fibrosis and slow down the
progression of CKD [118]. Cyclic azapeptides could also be used as a peptidomimetic therapy for
CD36 inhibition [119]. It has also been shown that azapeptide EP80317 improved post-ischaemic
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damage caused by myocardial infarction/myocardial infarction by (i) inhibiting CD36 activity and (ii)
transiently reducing peripheral lipolysis, thus preventing the movement of FAs from adipose tissue into
the blood and other tissues [120]. The synthetic amphipathic helical peptides ELK (ELK-SAHPs) that
target CD36 could also inhibit CD36 expression, and ameliorated lung inflammation and function [121].
Theoretically, blocking major receptors/transporters involved in renal fatty acid absorption can
represent an innovative treatment for patients with CKD. However, response to the treatment and
potential side effects of this approach need further evidence from clinical data.
5.5. SREBP-1 Inhibitors
As discussed above, SREBPs are transcription factors that govern cholesterol biosynthesis and
transport, and FA biosynthesis. In animals, the renal expression of sterol regulatory factor binding
proteins (SREBP-1 and SREBP-2) in the HFD group was found significantly increased as compared with
that of lean mice, causing the accumulation of cholesterol and triglycerides in the renal parenchyma,
and the induction of pro-fibrotic genes such as type IV collagen and fibronectin [122]. Insulin-treated
diabetic rats showed reduced SREBP-1 expression and triglyceride accumulation, suggesting that the
treatment of diabetic rats with insulin could inhibit the expression of SREBP-1 in the kidneys and
reduce the accumulation of triglycerides [123]. Reduction of SREBP-1 expression using ENOblock
reduced the accumulation of lipids in the kidneys of type 2 diabetic mice and reduced the degree of
fibrosis and inflammation [124].
5.6. Other Targets
Another signaling pathway involved in adipogenesis that represents an intriguing drug target for
the treatment of CKD is the Janus-activated kinase/signal transducer and activator of transcription
(JAK-STAT) pathway. In fact, in both patients and animals with CKD, the overexpression and/or
hyperactivation of the JAK-STAT signaling pathway appeared to worsen the kidney injury [125].
While no studies are available on the therapeutic role of JAK inhibitors in patients with CKD, it is
conceivable that efficient inhibition of this pathway may contribute to minimize the renal dysfunction.
JAK inhibitors are already safely administered for the treatment of a spectrum of hematological diseases
(e.g., leukemia) and autoimmune disorders (e.g., rheumatoid arthritis and psoriasis) [126–129].
The role of adrenocortical hormones in kidney and adipose tissues is well characterized. Indeed,
glucocorticoids and aldosterone-based mineralocorticoid drugs are effective in the treatment of CKD,
especially for their anti-inflammatory effect [130]. Nonetheless, methylprednisolone has also been
shown to inhibit the Wnt/b-catenin signaling pathway in murine subcutaneous and visceral adipose
tissue and to increase the expression of ATGL and hormone sensitive lipase (HSL) in subcutaneous
adipose tissue. The induction of ATGL and HSL ultimately reduced the animal body fat and
weight [131]. In addition, dexamethasone selectively inhibits the glucocorticoid receptor, thereby
inhibiting the expression of pro-inflammatory adipokines [123].
Statins are competitive inhibitors of the HMG-CoA reductase, the rate-limiting enzyme of
the mevalonate pathway, and are widely used to reduce total cholesterol, LDL, triglycerides, and
HDL. The cardiovascular and renal protective effect of lowering cholesterol in patients with kidney
dysfunction is still controversial. Fluvastatin did not reduce rates of coronary intervention procedures
or mortality in renal transplant recipients [132]. Conversely, the double-blind SHARP study (Study of
Heart and Renal Protection) on over nine thousand patients with CKD found that simvastatin in
combination with ezetimibe (inhibitor of cholesterol intestinal absorption) reduced total cholesterol,
LDL and the incidence of major atherosclerotic events, but no benefit to the kidney function was
observed [133]. Finally, a recent retrospective cohort study by Hu et al. showed that patients with CKD
stage 3B-5 taking statins have a significantly lower proteinuria as compared with those patients who
were not taking statins (Odds Ratio: 0.68, 95% CI 0.48–0.95) [134]. A summary of the most relevant
studies on lipid-lowering drugs for the treatment of CKD is reported in Table 1.
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Table 1. Main preclinical/clinical studies on the effect of lipid-lowering drugs on kidney function.




































ENOblock Mouse enolase Inflammation ↓Tubulointerstitial fibrosis ↓ [124]
Statin Mouse/Human HMG-CoAreductase Proteinuria ↓ [134]
CA; cholic acid, FXR; farnesoid x receptor, HMG-CoA; β-Hydroxy-β-Methylglutaryl-Coenzyme A, HOMA;
homeostasis model assessment, OCA; obeticholic acid, PPAR; peroxisome proliferator activated receptor, RXR;
retinoid X receptor, TG; triglyceride, TGR5; G-protein-coupled bile acid receptor.
5.7. Non-Targeted Therapies
Nearly 80% of the world’s population, especially in developing countries, rely on botanical drugs
as part of their healthcare [136]. In 2006, the annual cost of using herbal and dietary supplements
exceeded $60 billion, accounting for approximately 20% of the total pharmaceutical market [137].
Traditional herbal medicine is usually less noxious and may represent a valid therapeutic option
in CKD. After 5 weeks of thymol ingestion (extract of Thymus polytrichus), blood glucose, insulin
and triglycerides levels, urinary glucose, urea, urinary protein levels and renal weight markedly
declined in mice with HFD-induced progressive nephropathy. At the histopathological level, a
lower degree of extracellular mesangial matrix expansion and glomerular sclerosis was observed in
the HFD+thymol group as compared to the HFD one [138]. Rats with ORG treated with Tribulus
terrestris L (Zygophyllaceae) for 8 weeks showed reduced body weight, blood pressure, serum cystatin C
(a marker of kidney injury) and cholesterol levels as compared to the untreated ORG rats. Tribulus
terrestris L reduced the energy consumption and the hemorrhagic tendency of these animals and
improved their response to acute phase reactants [139]. Another plant belonging to the Tribulus
terrestris family is Coptis chinensis, which is widely used in clinical practice because of its hypoglycemic
and hypolipidemic effects. In the kidney tissue of ORG rats exposed to Coptis chinensis there was a
reduced expression of NACHT, LRR and PYD domains-containing protein 3 (NALP3, cryopyrin) and
inhibition of the NF-κB signaling [140]. According to Yang et al., troxerutin (contained in rue and
sophora flowers) has positive effects on lipid metabolism throughout the body. Single-cell sequencing
showed that troxerutin reduced the accumulation of serine-related lipids and oxidative stress in renal
tubular epithelial cells [141]. Emodin (RH) and danshensu (DSS) (salvianic acid A) induced apoptosis
Nutrients 2019, 11, 722 10 of 21
by up-regulating BCL-2 and down-regulating BAX. The renal function, blood supply, and fibrosis of
CKD rats treated with RH and DSS were greatly improved, perhaps due to the inhibition of the
TGF-β/SMAD3 pathway [142]. Finally, a population-based follow-up study has shown that traditional
herbal medicine significantly reduced the mortality rate of patients with CKD [143]. It is interesting to
point out that in the CKD 5D (dialysis) population, 18% used herbal medicine and 63% tried herbal
medicine [144]. However, because herbal and dietary supplements may interact with prescribed drugs,
attention should be paid to unexpected drug-herb interactions, which can reduce the overall efficacy
of the treatment or expose the patients to life-threatening toxic effects [145,146].
5.8. Lifestyle Modification
Currently, the nutritional treatment of CKD revolves around a limited intake of salts, proteins,
and phosphates. However, complementary and alternative medicine is increasingly applied in the
treatment of CKD in order to facilitate the replenishment of several micronutrients that are poorly
absorbed from the diet due to often co-existing metabolic and nutritional disorders in these patients,
or that are lost during hemodialysis [147]. If ectopic lipid accumulation is indeed associated with
CKD, the risk of developing CKD as well as its progression could be decreased also by reducing
systemic lipid levels and controlling the BMI. A clinical study has shown that weight loss promoted
the anti-proteinuria effect of angiotensin II receptor blockers in CKD patients [148]. These findings
are entirely consistent with those of previous studies, which emphasized the benefit of controlling
the BMI in patients with CKD [149,150]. A publication focusing on dietary recommendations for
patients with CKD, indicated that the top 10 most commonly appearing ingredients in complementary
and alternative medicine (e.g., dandelion, parsley, juniper, celery, and stinging nettle) have lipid- and
weight-lowering effects [151]. Over the past three decades, most research on defining the optimal diet
for early CKD patients has emphasized the value of a low-protein diet [152–154]. However, according
to the Kidney Diseases Dietary Improvement (MDRD) study, a low-protein diet may not have an
overall benefit in patients with CKD [155]. Even more surprising, a 4-year follow-up study from
the MDRD cohort showed that CKD patients with a very low-protein diet had the highest mortality
risk [156]. Therefore, whether CKD patients need to adopt a low-protein diet is still controversial and
perhaps lipids rather than proteins represent the major enemy in CKD.
An observational cohort study on 3972 CKD participants showed that excessive consumption of
processed and fried foods was independently associated with a higher mortality in CKD patients.
Conversely, fruit- and vegetables-based diets decreased the mortality rate of patients with CKD [157,158].
Azadbakht et al. interviewed 41 patients with type 2 diabetes and found that the inclusion of soybeans
in the diet significantly reduced the total cholesterol, LDL cholesterol, serum triglyceride, and
serum C-reactive protein levels, proteinuria and urinary creatinine [158]. A meta-analysis on 280
participants showed that serum creatinine, serum phosphate, C-reactive protein, and protease levels
were dramatically lower in patients with CKD after a period of soy isoflavone consumption [159].
This diet structure, besides reducing body weight, could also reduce the urine parameters of kidney
injury and the potential production of uremic toxins, which will undoubtedly delay the progression
of CKD [160,161]. A large-scale (2417 participants), population-based study has shown that the
lacto-vegetarian dietary pattern (characterized by high intakes of fruits, vegetables, low-fat dairy
products, and olive oil) has a protective effect on CKD onset [162]. A similar study suggests that vegan
(Odds Ratio: 0.87 (0.77–0.99), p = 0.041] and ovo-lacto vegetarian diets (Odds Ratio: 0.84 (0.78–0.90),
p < 0.001) can reduce the risk of developing CKD [163]. The Dietary Approaches to Stop Hypertension
diet (DASH) and the Mediterranean diet, which are similar in structure to the lacto-vegetarian and
ovo-lacto vegetarian dietary pattern, also control weight and prevent hypertension, diabetes, and
urinary albumin, thereby improving renal function and reducing the risk of kidney damage [164–168].
However, the results in humans are diverse and largely unclear. For example, Diaz-Lopez et al., in a
1-year study of dietary intervention in randomized clinical trials, found that the Mediterranean diet
had no beneficial effect on kidney function, perhaps due to the limited time of the intervention [169].
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Polyunsaturated fatty acids (n-3 PUFAs) can be beneficial in patients with CKD. They
are involved in immune regulation, inflammatory pathways, metabolic pathways of various
substances, signal transduction, and cell membrane formation, in addition to lowering blood
pressure and triglycerides [170,171]. Another crucial finding is that taking n-3 PUFAs can prevent
inflammation-related muscle loss in IgA nephropathy [172]. This points to the potential value of
n-3 PUFAs for CKD treatment. The n-3 PUFAs mainly include α-linoleic acid, eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA). While n-3 PUFAs cannot be synthesized in the human body,
they can be derived directly via fish and fish oil consumption or can be converted from α-linoleic
acid. The addition of n-3 PUFA to the diet of obese CKD patients has attracted intense discussion and
extensive attention. Three meta-analyses have shown that supplementation with n-3 PUFA after kidney
transplantation decreased triglycerides and diastolic blood pressure levels and increased HDL levels,
suggesting that n-3 PUFA may be beneficial for patients with kidney disease [173–175]. Recent studies
have shown that oral administration of EPA and DHA in patients with kidney disease reduced average
daily creatinine and proteinuria levels, with long-term benefits [176,177]. There are also randomized
controlled trials in which orally administered fish oil delayed IgA nephropathy progression and
reduced overall mortality [178]. Rats who underwent 5/6 nephrectomy and were treated with n-3
PUFAs, showed reduced expression of SREBP-1, and limited inflammation in comparison with
the 5/6 nephrectomy control animals [179]. Furthermore, a randomized controlled trial found
that after supplementation with n-3 PUFA, multiple markers of renal injury, such as Neutrophil
Gelatinase-Associated Lipocalin (NGAL), N-acetyl-beta-(D)-glucosaminidase (NAG), and proteinuria,
were significantly reduced [180]. The pieces of evidence reviewed here seem to point to the beneficial
effects of n-3 PUFA in patients with CKD.
6. Conclusions and Perspectives
The present review has discussed the effects of lipid accumulation in the kidneys by presenting
the possible molecular mechanisms underlying the link between renal lipid accumulation and CKD,
and has provided the theoretical bases for lowering circulating lipid levels in patients with CKD. It is
generally accepted that an excess of lipid accumulation in the renal parenchyma is relevant in CKD
development and can extend the damage at the tubular and glomerular level. Such evidence indicates
that a lipid-lowering pharmacological approach combined with a substantial lifestyle change should
be considered as part of CKD therapy. However, human intervention studies on lipid accumulation
require a large amount of data for randomized controlled trials, although, there are quite a few
difficulties and limitations in the evaluation of the effects of lipid metabolism on the kidney by
randomized controlled trials. Besides, several questions still remain to be answered, for example
regarding the lipid-regulating factors or the development of target therapeutic drugs.
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